611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA
Reg. FD
Material disclosure
Provides Business Update and Reports Second Quarter 2025 Financial Results
Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
News, Securities Holder Rights or Indentures, Material Contracts
Shareholder votes
Provides Business Update and Reports First Quarter 2025 Financial Results
Annual Report to Security Holders
Q2
Q1
FY 2024
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement
Correspondence
Submission Upload